<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15253">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02908308</url>
  </required_header>
  <id_info>
    <org_study_id>TTM-2</org_study_id>
    <nct_id>NCT02908308</nct_id>
  </id_info>
  <brief_title>Hypothermia or Normothermia-Targeted Temperature Management After Out-of-hospital Cardiac Arrest-trial</brief_title>
  <acronym>TTM-2</acronym>
  <official_title>Hypothermia or Normothermia-Targeted Temperature Management After Out-of-hospital Cardiac Arrest. A Randomized, Parallel Groups, Assessor Blinded, Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Niklas Nielsen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Region Skåne - Skånevård SUND</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsingborgs Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ILCOR guidelines recommend Target Temperature Management (TTM) to between 32°C and 36°C
      after out-of-hospital cardiac arrest, based on low quality evidence. In a previous trial,
      TTM at 33°C did not confer a survival benefit or improved neurological function, compared to
      TTM at 36°C. A lower target temperature might be beneficial compared with normothermia and
      early treatment of fever. Therefore the primary purpose of the TTM2-trial will be to study
      any differences in mortality, neurological function and quality of life between a target
      temperature of 33°C and standard care avoiding fever.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The TTM2 trial is a continuation of the collaboration that resulted in the previous Targeted
      Temperature Management after out-of-hospital cardiac arrest trial (hereafter: TTM1). With
      its planned size with it will supersede the TTM1 trial as the largest trial on temperature
      management as a post-cardiac arrest treatment.

      The TTM1 trial (NCT01020916) was a multicenter, multinational, outcome assessor-blinded,
      parallel group, randomised clinical trial comparing two strict target temperature regimens
      of 33°C and 36°C in adult patients, who have sustained return of spontaneous circulation and
      are unconscious after out-of-hospital cardiac arrest, when admitted to hospital. The trial
      did not demonstrate any difference in survival until end of trial (Hazard Ratio with a point
      estimate in favour of 36°C of 1.06 (95% confidence interval 0.89-1.28; P=0.51) or neurologic
      function at six months after the arrest, measured with CPC and mRS.

      The planned study is a international, multicenter, parallel group, non-commerical,
      randomized, superiority trial in which a target temperature om 33°C after cardiac arrest
      will be compared to normothermia and early treatment of fever.

      Patients eligible for inclusion will be unconscious adult patients with OHCA of a presumed
      cardiac cause with stable return of spontaneous circulation. Randomization will be performed
      by a physician in the emergency department, in the angiography suite or in the intensive
      care unit via web-based application using permuted blocks with varying sizes, stratified by
      site. Due to the nature of the intervention, health care staff will not be blinded to the
      intervention. However, the physicians who will assess outcomes will be blinded to
      temperature allocation, as will those who perform prognostication.

      The intervention period will commence at the time of randomization. Cooling in the
      hypothermia group will achieved by means of cold fluids and state-of-the-art cooling devices
      (intravascular or body-surface applied closed loop systems). The initial aim will be to
      achieve a body temperature below 33.0°C. When this has been achieved, the target temperature
      will be 33°C until 28 hours after randomisation. When 28 hours have passed, gradual
      rewarming at a rate of 1/3°C per hour will commence, this will allow 12 hours for rewarming.

      In the normothermia arm the aim will be to avoid a temperature greater than or equal to
      37.8°C using conservative measures. If a single temperature of 37.8° or greater is measured,
      active cooling with a device should be initiated and maintained until 40 hours after
      randomization.

      All subjects will be sedated, mechanically ventilated and hemodynamically supported
      throughout the intervention period of 40 hours. Subjects in both arms who remain comatose
      after 40h should be kept at a normothermic level (36.5 - 37.7°C) until 72h after
      randomization and active warming should be avoided.

      Subjects who remain unconscious four days after randomization will be assessed according to
      a conservative protocol based on the European Resuscitation Council's recommendations for
      withdrawal of life sustaining therapies.

      Follow up will be performed at:

      1 month (face-to-face or telephone. Assessment according to the CPC-scale) 6 moths
      (face-to-face, Assessment according to the GOSE-scale)
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>6 months</time_frame>
    <description>Landmark mortality at 180 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival until end of the trial</measure>
    <time_frame>180 days after randomization of last patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impairment</measure>
    <time_frame>180 days</time_frame>
    <description>Overall impairment assessed by the Glasgow Outcome Scale-extended (GOS-E)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>180 days</time_frame>
    <description>Health-related Quality of Life (EQ5-D)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Out-of-hospital Cardiac Arrest</condition>
  <arm_group>
    <arm_group_label>Normothermia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard care with early treatment of fever. Active temperature control with a device will be used if the patient develops a temperature greater than or equal 37.8°C.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypothermia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Targeted temperature management to 33°C for up to 28h.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Targeted temperature management to 33°C</intervention_name>
    <description>Rapid cooling to below 33°C, followed by temperature control at 33°C for up to 28h.</description>
    <arm_group_label>Hypothermia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard care with early treatment of fever</intervention_name>
    <description>Normothermia and standard care - use of a device for temperature control if temperature is greater than or equal to 37.8°C</description>
    <arm_group_label>Normothermia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  out-of-hospital cardiac arrest

          -  presumed cardiac cause of cardiac arrest

          -  unconscious with a FOUR-score &lt;M4 (not obeying verbal commands)

          -  stable return of spontaneous circulation (20 min)

          -  eligible for intensive care treatment without restrictions

        Exclusion Criteria:

          -  pregnancy (confirmed or suspected)

          -  intracerebral haemorrhage

          -  Initial temperature &lt;30°C

          -  On ECMO prior to ROSC

          -  Known disease making 180 day-survival unlikely

          -  More than 180 minutes from ROSC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niklas Nielsen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsingborgs lasarett, Region Skåne, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hans Friberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University Hospital, Lund, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tobias Cronberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University Hospital, Lund, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pascal Stammet, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier du Luxembourg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Hovdenes, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital, Oslo, Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Pellis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Santa Maria degli Angeli Hospital, Pordenone, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matt P Wise, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Wales, Cardiff, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cliffton W Callaway, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh, Pittsburgh, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian Storm, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité University Medicine, Berlin, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alain Cariou, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université Paris Descartes, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Erlinge, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University Hospital, Lund, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anders Åneman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liverpool Hospital, Sydney, Australia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian Rylander, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sahlgrenska University Hospital, Gothenburg, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Josef Dankiewicz, MD, PhD</last_name>
    <phone>+46734089480</phone>
    <email>ttm2@ttm2trial.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tobias Cronberg, MD, PhD</last_name>
    <phone>+4646171000</phone>
    <email>tobias.cronberg@med.lu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>General University Hospital</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Martino Hospital</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Maria degli Angeli Hospital</name>
      <address>
        <city>Pordenone</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Luxembourg</name>
      <address>
        <city>Luxembourg</city>
        <country>Luxembourg</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum, AMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeuwarden Hospital</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsingborgs Hospital</name>
      <address>
        <city>Helsingborg</city>
        <zip>251 87</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Geneva</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Italy</country>
    <country>Luxembourg</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://ttm2trial.org</url>
  </link>
  <reference>
    <citation>Nielsen N, Wetterslev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, Horn J, Hovdenes J, Kjaergaard J, Kuiper M, Pellis T, Stammet P, Wanscher M, Wise MP, Åneman A, Al-Subaie N, Boesgaard S, Bro-Jeppesen J, Brunetti I, Bugge JF, Hingston CD, Juffermans NP, Koopmans M, Køber L, Langørgen J, Lilja G, Møller JE, Rundgren M, Rylander C, Smid O, Werer C, Winkel P, Friberg H; TTM Trial Investigators.. Targeted temperature management at 33°C versus 36°C after cardiac arrest. N Engl J Med. 2013 Dec 5;369(23):2197-206. doi: 10.1056/NEJMoa1310519. Epub 2013 Nov 17.</citation>
    <PMID>24237006</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>February 13, 2017</lastchanged_date>
  <firstreceived_date>September 16, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Helsingborgs Hospital</investigator_affiliation>
    <investigator_full_name>Niklas Nielsen</investigator_full_name>
    <investigator_title>MD, PhD, Associate professor</investigator_title>
  </responsible_party>
  <keyword>Induced hypothermia</keyword>
  <keyword>Mild induced hypothermia</keyword>
  <keyword>Therapeutic hypothermia</keyword>
  <keyword>Cardiac arrest</keyword>
  <keyword>Out-of-hospital cardiac arrest</keyword>
  <keyword>Mortality</keyword>
  <keyword>Neurological function</keyword>
  <keyword>Randomised clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Arrest</mesh_term>
    <mesh_term>Hypothermia</mesh_term>
    <mesh_term>Out-of-Hospital Cardiac Arrest</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
